Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions

Bone

Volumn 77, Issue , 2015, Pages 50-56

  Newman, Christopher L ^a   Chen, Neal X ^b   Smith, Eric ^a   Smith, Mark ^a   Brown, Drew ^a   Moe, Sharon M ^b,c   Allen, Matthew R ^a,b  

^a Department of Anatomy and Cell Biology ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti sclerostin antibody; Chronic kidney disease; CKD MBD; PTH; Spine; Zoledronic acid

Indexed keywords

CALCIUM; PROTEIN ANTIBODY; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTIBODY; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; PARATHYROID HORMONE; SOST PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE DISEASE; BONE MASS; BONE REMODELING; BONE STRUCTURE; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; HYPERPARATHYROIDISM; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; PARATHYROID HORMONE BLOOD LEVEL; RAT; SINGLE DRUG DOSE; SPINE DISEASE; TRABECULAR BONE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE COURSE; DISEASE MODEL; GENETIC MARKER; IMMUNOLOGY; PATHOLOGY; SPINE;

ANIMALS; ANTIBODIES; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC MARKERS; PARATHYROID HORMONE; RATS; RENAL INSUFFICIENCY, CHRONIC; SPINE;

EID: 84928344693     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.04.021     Document Type: Article

References (45)

1. Jamal S.A., West S.L., Miller P.D. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2011, 23:1191-1198.
2. Nickolas T.L., McMahon D.J., Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006, 17:3223-3232.
3. Ensrud K.E., Lui L.-Y., Taylor B.C., Ishani A., Shlipak M.G., Stone K.L., et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007, 167:133-139.
4. Atsumi K., Kushida K., Yamazaki K., Shimizu S., Ohmura A., Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999, 33:287-293.
5. Nickolas T.L., Stein E.M., Dworakowski E., Nishiyama K.K., Komandah-Kosseh M., Zhang C.A., et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 2013, 28:1811-1820.
6. Parfitt A.M. A structural approach to renal bone disease. J Bone Miner Res 1998, 13:1213-1220.
7. Eswaran S.K., Gupta A., Adams M.F., Keaveny T.M. Cortical and trabecular load sharing in the human vertebral body. J Bone Miner Res 2006, 21:307-314.
8. Shipov A., Segev G., Meltzer H., Milrad M., Brenner O., Atkins A., et al. The effect of naturally occurring chronic kidney disease on the micro-structural and mechanical properties of bone. PLoS One 2014, 9:e110057.
9. Newman C.L., Moe S.M., Chen N.X., Hammond M.A., Wallace J.M., Nyman J.S., et al. Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease. PLoS One 2014, 9:e99262.
10. Iwasaki Y., Kazama J.J., Yamato H., Fukagawa M. Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 2011, 48:1260-1267.
11. Allen M.R., Chen N.X., Gattone V.H., Chen X., Carr A.J., LeBlanc P., et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int 2012, 24:1471-1481.
12. Aoki C., Uto K., Honda K., Kato Y., Oda H. Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy. Lab Invest 2013, 93:1170-1183.
13. Moe S.M., Chen N.X., Newman C.L., Gattone V.H., Organ J.M., Chen X., et al. A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res 2014, 29:902-910.
14. Cowley B.D., Grantham J.J., Muessel M.J., Kraybill A.L., Gattone V.H. Modification of disease progression in rats with inherited polycystic kidney disease. Yajkd 1996, 27:865-879.
15. Cowley B.D., Gudapaty S., Kraybill A.L., Barash B.D., Harding M.A., Calvet J.P., et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993, 43:522-534.
16. Moe S.M., Chen N.X., Seifert M.F., Sinders R.M., Duan D., Chen X., et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 2009, 75:176-184.
17. Hoff S., Halbritter J., Epting D., Frank V., Nguyen T.-M.T., van Reeuwijk J., et al. ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. Nat Genet 2013, 45:951-956.
18. Taskiran E.Z., Korkmaz E., Gucer S. Mutations in ANKS6 cause a nephronophthisis-like phenotype with ESRD. J Am Soc Nephrol 2014, 25(8):1653-1661.
19. Brown J.H., Bihoreau M.-T., Hoffmann S., Kränzlin B., Tychinskaya I., Obermüller N., et al. Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J Am Soc Nephrol 2005, 16:3517-3526.
20. Moe S.M., Chen N.X., Newman C.L., Organ J.M., Kneissel M., Kramer I., et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 2015, 30(3):499-509.
21. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
22. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
23. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595-608.
24. Jamal S.A., Bauer D.C., Ensrud K.E., Cauley J.A., Hochberg M., Ishani A., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007, 22:503-508.
25. Nickolas T.L., Leonard M.B., Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008, 74:721-731.
26. Dukas L., Schacht E., Stähelin H.B. In elderly men and women treated for osteoporosis a low creatinine clearance of <65ml/min is a risk factor for falls and fractures. Osteoporos Int 2005, 16:1683-1690.
27. Danese M.D., Kim J., Doan Q.V., Dylan M., Griffiths R., Chertow G.M. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006, 47:149-156.
28. Christov M., Pereira R., Wesseling-Perry K. Bone biopsy in renal osteodystrophy. Curr Opin Nephrol Hypertens 2013, 1.
29. Malluche H.H., Monier-Faugere M.C. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994, 4:1631-1642.
30. Ott S.M. Bone histomorphometry in renal osteodystrophy. Semin Nephrol 2009, 29:122-132.
31. Spasovski G.B. Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. Int J Artif Organs 2004, 27:918-923.
32. Barreto F.C., Barreto D.V., Moyses R.M.A., Neves C.L., Jorgetti V., Draibe S.A., et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 2006, 69:1852-1857.
33. Julian B.A., Laskow D.A., Dubovsky J., Dubovsky E.V., Curtis J.J., Quarles L.D. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991, 325:544-550.
34. Burr D.B. Why bones bend but don't break. J Musculoskelet Neuronal Interact 2011, 11.
35. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:578-588.
36. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
37. Malluche H.H., Porter D.S., Monier-Faugere M.-C., Mawad H., Pienkowski D. Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol 2012, 23:525-532.
38. Malluche H.H., Porter D.S., Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nat Publ Group 2013, 9:671-680.
39. Changes in skeletal collagen crosslinks and matrix hydration in high and low turnover chronic kidney disease 2014, 1-27.
40. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38:617-627.
41. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2011, 49:56-65.
42. Grey A., Bolland M.J., Horne A., Wattie D., House M., Gamble G., et al. Five years of anti-resorptive activity after a single dose of zoledronate - results from a randomized double-blind placebo-controlled trial. Bone 2012, 1-5.
43. Reid I.R., Lyles K., Su G., Brown J.P., Walsh J.P., del Pino-Montes J., et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5years. J Bone Miner Res 2011, 26:2261-2270.
44. Fuchs R., Phipps R. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 2008, 23(10):1689-1697.
45. Pfister T., Atzpodien E., Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003, 191:159-167.